urinarytractsupplements

chloelogoa

CANINE CYSTITIS-BACTERIAL

(URINARY TRACT INFECTIONS)

Supplements

talalogoa

Species affected: Cats, Dogs

Background: Certain breed types, families and individuals are prone to a greater incidence of infection.

Symptoms: Usually involve frequency of urination, household soiling, urinating just outside of a litterbox, hematuria, straining, and painful urination.

Diagnostics: Normally urine is bacteriostatic but when the pH, nutrient level and concentration of the urine becomes conducive to support greater levels of bacterial life, a bacterial infection can ascend from the urethra.

Special Notes: Any factor that contributes to stress, nutritional deficiency or imbalance, urinary stasis, or immune weakness can lead to cystitis.

Principles for Supplementation: Antibacterial action of herbs, nutrients, support healing of bladder wall and urethra.

CANINE AND FELINE PRODUCTS—CYSTITIS-BACTERIAL (URINARY TRACT INFECTIONS)
Formulas	Dosage	Mechanism/Purpose
Arthroplex	Cats: ½ capsule, sid Dogs: 1 capsule/25 lbs, bid	Glycosaminoglycans will support mucosal barrier of bladder wall and relieve pain.
Ba Zheng San	Cats: 2 pills, bid or tid Dogs: 2-4 pills, bid or tid	Decreases damp heat, promotes urination.
Chinese Herbal Bactolyte	Cats: 1 - 2 pills, bid	Antibacterial; use if bacterial infection is present.
Chinese Herbal Cystegen	Cats: 1 - 2 pills, bid Dogs: 1 pill/10 lbs, bid	Clears heat, reduces UT inflammation; bacterial infection may or may not be present.
CranGuard	Cats: ¼ - ½ capsule, tid Dogs: ½ - 2 capsules, tid	Antibacterial, blocks attachment of bacteria to bladder wall, acidifies urine.

Source
Veterinarian’s Desk Reference of Natural Medicines
This guide is intended for use by licensed veterinarians only. While pet owners may find this information useful, they should not attempt to self-diagnose their animal friends. The Veterinary Institute of Integrative Medicine always recommends that your animal’s healthcare be directed under the guidance of a veterinarian.
http://www.viim.org/therapeutics/VDR_2004a_final.pdf